Table 3 Therapies for HAE supported by high level of evidence
HAE specific treatment | Product name and company | Mechanism of Action | Approved Indications In Canada | Dose | Adverse Events |
|---|---|---|---|---|---|
C1-INH – Plasma | Berinert® (CSL) | Replaces CI-INH | Acute treatment | 20 IU/Kg intravenous | Anaphylaxis/Thrombosis (rare);Transmission of infectious agents (theoretical) |
|  | Cinryze® (Shire) | Replaces CI-INH | Long term Prophylaxis | 1000 IU q3-4 days intravenous | Anaphylaxis/Thrombosis (rare);Transmission of infectious agents (theoretical) |
– Recombinant | Rhucin® (Pharming) | Replaces CI-INH | Not licensed | 50 U/Kg Intravenous | Anaphylaxis (rare) |
Ecallantide | Kalbitor® (Dyax) | Inhibits plasma kallikrein | Not licensed | 30 mg subcutaneous injection | Anaphylaxis (uncommon) |
Icatibant | Firazyr® (Shire) | Blocks bradykinin 2 receptor | Acute treatment | 30 mg subcutaneous injection | Pain, swelling, pruritis at injection site (common) |
| Â | Â | Â | Â | Â | Exacerbation of coronary artery disease (theoretical) |